Carlsmed, Inc.
CARLCarlsmed, Inc. in brief
Carlsmed, Inc. is a listed company in the Healthcare sector, based in Carlsbad, California, USA. Its market value was $420 M on 29 October 2026, which makes it the 13,346th largest listed company in the world and the 2,645th largest in the USA on this site. In the year to December 2025 it had sales of $51 M and a net loss of $30 M. Michael Cordonnier is its chief executive. Its shares trade under the symbol CARL (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Carlsmed, Inc.
We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a focus on becoming the standard of care for spine fusion surgery. Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The aprevo Technology Platform was designed to address the limitations of traditional lumbar and cervical spine fusion surgery, aiming to optimize patient outcomes and reduce the need for revision surgeries.
Our technology is powered by AI-enabled, outcome-based algorithms that provide personalized surgical plans for spine fusion. The aprevo surgical kit delivered to customers includes interbody implants for a custom vertebral fit for each patient’s unique pathology and bone topography, and single-use surgical instruments. The aprevo Technology Platform supports surgeons in achieving proper spinal alignment for patients with degenerative disc disease, which can improve clinical outcomes and reduce the likelihood of revision surgeries. We currently market the aprevo Technology Platform for lumbar and cervical spine fusion surgeries.
From the company's annual report filed with the US SEC: read the report
Carlsmed, Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 24 July 2025; shares registered for exchange trading on 21 July 2025.
Events of Carlsmed, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,684 (Aug 2026) · #2,666 (Oct 2026) · #2,648 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 5.8×
- Price / book
- 4.2×
- Free cash flow yield
- -7.1%
- Net margin (TTM)
- -55.8%
- Operating margin
- -60.5%
- Return on equity
- -40.5%
- Liabilities / assets
- 24.0%
- Net debt
- $-70M
- Revenue growth
- +86.0%
- R&D / revenue
- 33.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $51M | +86.0% | $-31M | $-30M | -58.7% |
| Dec 2024 | $27M | — | $-24M | $-24M | -89.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-29M | $1M | $-30M | $-2.12 | — |
| Dec 2024 | $-25M | $0M | $-26M | $-6.11 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $22M (+64.9% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 30, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 8, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 3, 20268-KCurrent reportShareholder vote
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
- Apr 22, 2026DEF 14AProxy statement
- Feb 25, 202610-KAnnual report · period to Dec 2025
- Feb 25, 20268-KCurrent reportResults of operations
Official filings of Carlsmed, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $51 M
- Operating income
- $-31 M
- Net income
- $-30 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $130 M
- Total liabilities
- $31 M
- Total equity
- $99 M
As of December-2025
Top 87 institutional investors in Carlsmed, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Parkman Healthcare Partners LLC | 779,757 | +182,439 (+30.54%) | 2.85% | $11 M | Nov 16, 2026 |
| 2 | Janus Henderson Group Ltd. | 726,196 | — | 2.65% | $10 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 581,660 | +49,067 (+9.21%) | 2.12% | $8 M | Nov 13, 2026 |
| 4 | Pier Capital, LLC | 518,711 | +145,034 (+38.81%) | 1.89% | $7 M | Nov 13, 2026 |
| 5 | Cadian Capital Management, LP | 500,096 | New | 1.82% | $7 M | Nov 16, 2026 |
| 6 | Point72 Asset Management, L.P. | 495,820 | New | 1.81% | $7 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 281,407 | +42,680 (+17.88%) | 1.03% | $4 M | Nov 13, 2026 |
| 8 | Palumbo Wealth Management LLC | 265,891 | -1,407 (-0.53%) | 0.97% | $4 M | Nov 13, 2026 |
| 9 | Russell Investments Group, Ltd. | 257,805 | +118,663 (+85.28%) | 0.94% | $4 M | Nov 6, 2026 |
| 10 | Geode Capital Management, LLC | 234,901 | +30,246 (+14.78%) | 0.86% | $3 M | Nov 6, 2026 |
| 11 | D. E. Shaw & Co., Inc. | 150,842 | +90,403 (+149.58%) | 0.55% | $2 M | Nov 16, 2026 |
| 12 | State Street Corp | 138,144 | +5,061 (+3.80%) | 0.50% | $2 M | Nov 12, 2026 |
| 13 | AQR Capital Management LLC | 86,657 | -5,502 (-5.97%) | 0.32% | $1 M | Nov 16, 2026 |
| 14 | Schonfeld Strategic Advisors LLC | 80,089 | -144,715 (-64.37%) | 0.29% | $1 M | Nov 16, 2026 |
| 15 | Tocqueville Asset Management L.P. | 80,000 | New | 0.29% | $1 M | Nov 13, 2026 |
| 16 | Citadel Advisors LLC | 67,706 | -34,020 (-33.44%) | 0.25% | $1 M | Nov 16, 2026 |
| 17 | Northern Trust Corp | 67,659 | +3,026 (+4.68%) | 0.25% | $1 M | Nov 16, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 65,860 | +15,932 (+31.91%) | 0.24% | $1 M | Nov 13, 2026 |
| 19 | BNP Paribas Financial Markets | 62,570 | +22,619 (+56.62%) | 0.23% | $1 M | Nov 12, 2026 |
| 20 | Millennium Management LLC | 60,617 | -235,290 (-79.51%) | 0.22% | $1 M | Nov 16, 2026 |
| 21 | Vanguard Portfolio Management LLC | 57,983 | +1,035 (+1.82%) | 0.21% | $1 M | Nov 13, 2026 |
| 22 | Goldman Sachs Group Inc | 52,592 | -10,534 (-16.69%) | 0.19% | $1 M | Nov 16, 2026 |
| 23 | Kornitzer Capital Management Inc /KS | 49,769 | -1,919 (-3.71%) | 0.18% | $1 M | Nov 3, 2026 |
| 24 | Two Sigma Investments, LP | 48,107 | +30,099 (+167.14%) | 0.18% | $1 M | Nov 16, 2026 |
| 25 | Boston Partners | 43,923 | +21,548 (+96.30%) | 0.16% | $1 M | Nov 10, 2026 |
Show all 87: investors 26 to 87
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Trexquant Investment LP | 40,655 | +29,654 (+269.56%) | 0.15% | $1 M | Nov 16, 2026 |
| 27 | Morgan Stanley | 38,427 | +7,728 (+25.17%) | 0.14% | $1 M | Nov 13, 2026 |
| 28 | Bridgeway Capital Management, LLC | 32,006 | +7,006 (+28.02%) | 0.12% | $0 M | Nov 16, 2026 |
| 29 | Empowered Funds, LLC | 32,006 | New | 0.12% | $0 M | Nov 13, 2026 |
| 30 | XTX Topco Ltd | 31,132 | New | 0.11% | $0 M | Nov 16, 2026 |
| 31 | Walleye Capital LLC | 27,787 | New | 0.10% | $0 M | Nov 13, 2026 |
| 32 | Jump Financial, LLC | 26,400 | +6,986 (+35.98%) | 0.10% | $0 M | Nov 13, 2026 |
| 33 | Jane Street Group, LLC | 26,370 | -47,019 (-64.07%) | 0.10% | $0 M | Nov 12, 2026 |
| 34 | Charles Schwab Investment Management Inc | 20,426 | +3,150 (+18.23%) | 0.07% | $0 M | Nov 16, 2026 |
| 35 | Prudential Financial Inc | 19,618 | New | 0.07% | $0 M | Nov 16, 2026 |
| 36 | Bank of New York Mellon Corp | 19,024 | +1,572 (+9.01%) | 0.07% | $0 M | Nov 5, 2026 |
| 37 | Jpmorgan Chase & Co | 18,162 | +12,898 (+245.02%) | 0.07% | $0 M | Nov 12, 2026 |
| 38 | Zevenbergen Capital Investments LLC | 17,900 | +6,000 (+50.42%) | 0.07% | $0 M | Oct 8, 2026 |
| 39 | Occudo Quantitative Strategies LP | 17,586 | New | 0.06% | $0 M | Nov 16, 2026 |
| 40 | Mercer Global Advisors Inc /adv | 17,057 | -405 (-2.32%) | 0.06% | $0 M | Nov 16, 2026 |
| 41 | Alpine Woods Capital Investors, LLC | 16,044 | +502 (+3.23%) | 0.06% | $0 M | Nov 13, 2026 |
| 42 | Bank Of America Corp /de/ | 15,512 | +5,116 (+49.21%) | 0.06% | $0 M | Nov 16, 2026 |
| 43 | Centiva Capital, LP | 14,716 | -175 (-1.18%) | 0.05% | $0 M | Nov 13, 2026 |
| 44 | Janney Montgomery Scott LLC | 14,025 | +1,000 (+7.68%) | 0.05% | $0 M | Nov 12, 2026 |
| 45 | Board of Trustees of The Leland Stanford Junior University | 12,516 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 46 | UBS Group AG | 12,168 | -4,581 (-27.35%) | 0.04% | $0 M | Nov 10, 2026 |
| 47 | Quadrature Capital Ltd | 12,113 | New | 0.04% | $0 M | Nov 13, 2026 |
| 48 | Entropy Technologies, LP | 11,345 | New | 0.04% | $0 M | Nov 13, 2026 |
| 49 | Gsa Capital Partners LLP | 11,249 | New | 0.04% | $0 M | Nov 16, 2026 |
| 50 | Nuveen, LLC | 9,932 | New | 0.04% | $0 M | Nov 10, 2026 |
| 51 | Rhumbline Advisers | 9,921 | +4,133 (+71.41%) | 0.04% | $0 M | Nov 10, 2026 |
| 52 | Deutsche Bank AG\ | 7,119 | -3,061 (-30.07%) | 0.03% | $0 M | Nov 6, 2026 |
| 53 | Citigroup Inc | 4,474 | +97 (+2.22%) | 0.02% | $0 M | Nov 4, 2026 |
| 54 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 4,043 | +150 (+3.85%) | 0.01% | $0 M | Nov 16, 2026 |
| 55 | Vanguard Global Advisers, LLC | 3,626 | +49 (+1.37%) | 0.01% | $0 M | Nov 13, 2026 |
| 56 | Barclays PLC | 3,298 | +1,855 (+128.55%) | 0.01% | $0 M | Nov 6, 2026 |
| 57 | Wells Fargo & Company/mn | 2,424 | -5,299 (-68.61%) | 0.01% | $0 M | Nov 16, 2026 |
| 58 | New York State Common Retirement Fund | 1,800 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 59 | Police & Firemen's Retirement System of New Jersey | 1,258 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 60 | Armstrong Advisory Group, Inc | 1,234 | 0 (0.00%) | 0.00% | $0 M | Oct 9, 2026 |
| 61 | FMR LLC | 1,165 | +10 (+0.87%) | 0.00% | $0 M | Nov 10, 2026 |
| 62 | Arax Advisory Partners | 939 | +190 (+25.37%) | 0.00% | $0 M | Nov 12, 2026 |
| 63 | Tower Research Capital LLC (TRC) | 833 | -372 (-30.87%) | 0.00% | $0 M | Nov 16, 2026 |
| 64 | Quarry LP | 737 | New | 0.00% | $0 M | Nov 16, 2026 |
| 65 | Legal & General Group Plc | 685 | -339 (-33.11%) | 0.00% | $0 M | Nov 16, 2026 |
| 66 | Ameritas Investment Partners, Inc. | 565 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 67 | Jones Financial Companies Lllp | 530 | -100 (-15.87%) | 0.00% | $0 M | Nov 13, 2026 |
| 68 | Royal Bank Of Canada | 442 | -58 (-11.60%) | 0.00% | $0 M | Nov 16, 2026 |
| 69 | Farther Finance Advisors, LLC | 261 | +165 (+171.88%) | 0.00% | $0 M | Oct 8, 2026 |
| 70 | Sterling Capital Management LLC | 217 | +112 (+106.67%) | 0.00% | $0 M | Oct 22, 2026 |
| 71 | Steward Partners Investment Advisory, LLC | 217 | New | 0.00% | $0 M | Nov 13, 2026 |
| 72 | Allworth Financial LP | 203 | +23 (+12.78%) | 0.00% | $0 M | Nov 17, 2026 |
| 73 | EverSource Wealth Advisors, LLC | 145 | -62 (-29.95%) | 0.00% | $0 M | Nov 4, 2026 |
| 74 | Osaic Holdings, Inc. | 120 | +100 (+500.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 75 | California State Teachers Retirement System | 114 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 76 | Physician Wealth Advisors, Inc. | 91 | New | 0.00% | $0 M | Oct 20, 2026 |
| 77 | Root Financial Partners, LLC | 85 | New | 0.00% | $0 M | Oct 21, 2026 |
| 78 | Essential Partners LLC | 67 | -1 (-1.47%) | 0.00% | $0 M | Oct 14, 2026 |
| 79 | SJS Investment Consulting Inc. | 54 | +35 (+184.21%) | 0.00% | $0 M | Oct 26, 2026 |
| 80 | IFP Advisors, Inc | 52 | -1 (-1.89%) | 0.00% | $0 M | Oct 16, 2026 |
| 81 | True Wealth Design, LLC | 47 | -5 (-9.62%) | 0.00% | $0 M | Oct 13, 2026 |
| 82 | Fortitude Family Office, LLC | 41 | +11 (+36.67%) | 0.00% | $0 M | Oct 14, 2026 |
| 83 | Rothschild Investment LLC | 24 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 84 | GAMMA Investing LLC | 12 | New | 0.00% | $0 M | Oct 8, 2026 |
| 85 | Caitong International Asset Management Co., Ltd | 11 | +4 (+57.14%) | 0.00% | $0 M | Oct 29, 2026 |
| 86 | Clearstead Advisors, LLC | 1 | -4 (-80.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 87 | JPL Wealth Management, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Carlsmed, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Janus Henderson Venture FundJanus Investment Fund | 609,059 | $6 M | 2.2% | 0.17% | +3.6% | Jun 30, 2026 |
| 🇺🇸 Janus Henderson Small Cap Value FundJanus Henderson Investors US LLC | 343,579 | $4 M | 1.3% | 0.28% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 213,041 | $2 M | 0.78% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 158,583 | $2 M | 0.58% | <0.01% | −19% | Jun 30, 2026 |
| 🇸🇪 SEB Nordamerikafond SmåbolagSEB Funds AB | 130,204 | $1 M | 0.48% | 0.48% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 102,893 | $1 M | 0.38% | 0.13% | +105% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 93,117 | $1 M | 0.34% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 73,487 | $1 M | 0.27% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 59,725 | $1 M | 0.22% | 0.08% | new | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 41,408 | $0 M | 0.15% | <0.01% | +23% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 44,451 | $0 M | 0.16% | <0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 41,737 | $0 M | 0.15% | <0.01% | +126% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 36,140 | $0 M | 0.13% | <0.01% | +3.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 28,345 | $0 M | 0.10% | 0.02% | +40% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 25,000 | $0 M | 0.09% | 0.18% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 20,399 | $0 M | 0.07% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 16,880 | $0 M | 0.06% | <0.01% | +6.6% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 12,014 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 12,922 | $0 M | 0.05% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 11,392 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,100 | $0 M | 0.04% | <0.01% | +7.8% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 8,160 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 6,700 | $0 M | 0.02% | <0.01% | +347% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 6,428 | $0 M | 0.02% | <0.01% | +93% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,976 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 4,974 | $0 M | 0.02% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 4,034 | $0 M | 0.01% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 4,439 | $0 M | 0.02% | <0.01% | −8.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 3,774 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 3,736 | $0 M | 0.01% | <0.01% | −10% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,600 | $0 M | 0.01% | <0.01% | +225% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,500 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,883 | $0 M | 0.01% | <0.01% | −27% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 2,603 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 2,166 | $0 M | <0.01% | <0.01% | +36% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,915 | $0 M | <0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 1,452 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,062 | $0 M | <0.01% | <0.01% | +3.2% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,203 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,200 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 1,200 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,178 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,014 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 616 | $0 M | <0.01% | <0.01% | +6.0% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 720 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 578 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 687 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 669 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 557 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 613 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 582 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 473 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 474 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 565 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 559 | $0 M | <0.01% | <0.01% | +6.5% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 381 | $0 M | <0.01% | <0.01% | +30% | May 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 413 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 342 | $0 M | <0.01% | <0.01% | +143% | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 306 | $0 M | <0.01% | <0.01% | −26% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 336 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 299 | $0 M | <0.01% | <0.01% | −29% | May 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 306 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 234 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 193 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 152 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Carlsmed, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jeffrey BertoliniChief Operating Officer | Option exercise10b5-1 plan | +747 | $5.915 | $4 K | 23,236 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Sell10b5-1 plan | -747 | $15.15 | $11 K | 22,489 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Option exercise10b5-1 plan | +243 | $2.232 | $542 | 22,732 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Sell10b5-1 plan | -243 | $15.80 | $4 K | 22,489 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Option exercise10b5-1 plan | +747 | $5.915 | $4 K | 23,236 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Sell10b5-1 plan | -747 | $14.39 | $11 K | 22,489 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Option exercise10b5-1 plan | +243 | $2.232 | $542 | 22,732 | Form 4 |
| filed | Jeffrey BertoliniChief Operating Officer | Sell10b5-1 plan | -243 | $13.99 | $3 K | 22,489 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Carlsmed, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $15.00, raising $100.5M · IPO calendar
Stock splits: 1-for-5.59 reverse split
Fails to deliver
- : 12 shares at $15.31
- : 115 shares at $15.42
- : 528 shares at $14.47
- : 180 shares at $14.78
- : 2 shares at $14.05
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Carlsmed, Inc. scorecard#
Passes 5 of the 16 checks that could be worked out: strongest in financial health (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.2×Price to book 4.2× against Healthcare's median of 3.1×.
- ✗Price to sales below its peers' median5.8×Price to sales 5.8× against Healthcare's median of 3.8×.
- ✗Free cash flow yield above 5%-7.1%Free cash flow is -7.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year86.0%Revenue up 86.0% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.12 vs -6.11Diluted EPS -2.12 in fiscal 2025 against -6.11 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-60.5%-60.5% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%-209.8%-209.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health4 of 5
- ✓Short-term assets cover short-term liabilities8.9×Current ratio 8.87 at the end of fiscal 2025.
- ✓Debt below equity0.2×Debt to equity 0.16 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $70 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-21.4×Operating income -21.4 times interest in fiscal 2025.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- ✓Altman Z-score outside the distress zone7.62Z-score 7.62 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year249.8%Diluted shares up 249.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Carlsmed, Inc.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -60.5% | -7.7% | |
| Net margin | -58.7% | -8.1% | |
| Return on equity | -209.8% | -36.9% | |
| Revenue growth | 86.0% | 10.2% | |
| Debt to equity | 0.16× | 0.45× | |
| Free cash flow margin | -58.6% | -1.3% |
5of 9on the Piotroski tests of financial strength
- Net loss of $30 million.
- Free cash flow was negative: -$30 million.
- The share count rose 249.8% in the year.
- Operating income covers the interest bill only -21.4 times.
Carlsmed, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Revenue | 51+85.9%100% | 27—100% | |
| Cost of revenue | 12+75.2%24.7% | 7.1—26.2% | |
| Gross profit | 38+89.7%75.3% | 20—73.8% | |
| Research and development | 17+19.0%33.7% | 14—52.7% | |
| Selling and marketing | 35+63.1%69.3% | 21—79.0% | |
| General and administrative | 17+97.4%32.8% | 8.4—30.9% | |
| Operating expenses | 69+55.3%136% | 44—163% | |
| Operating income | −31—−60.5% | −24—−88.8% | |
| Interest and finance income | 2.7+103%5.3% | 1.3—4.9% | |
| Interest expense and finance costs | 1.4+8.3%2.8% | 1.3—4.9% | |
| Other non-operating income (expense) | 0.9—1.9% | −0.1—−0.5% | |
| Income tax | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −30—−58.7% | −24—−89.3% | |
| Earnings per share, basic | -2.12—— | -6.11—— | |
| Earnings per share, diluted | -2.12—— | -6.11—— | |
| Shares, weighted average (basic) | 14+250%— | 4.1—— | |
| Shares, weighted average (diluted) | 14+250%— | 4.1—— | |
| Balance sheet | |||
| Cash and cash equivalents | 86+114%65.9% | 40—77.4% | |
| Short-term investments | 24—18.4% | 0—0.0% | |
| Receivables | 11+67.9%8.7% | 6.8—13.1% | |
| Inventory | 1.8+85.4%1.4% | 1.0—1.9% | |
| Other current assets | 3.6+162%2.7% | 1.4—2.6% | |
| Current assets | 127+157%97.4% | 49—95.2% | |
| Property, plant and equipment | 1.5+472%1.1% | 0.3—0.5% | |
| Right-of-use (leased) assets | 1.8+11.1%1.4% | 1.6—3.2% | |
| Total assets | 130+151%100% | 52—100% | |
| Accounts payable | 4.5+85.8%3.4% | 2.4—4.7% | |
| Current liabilities | 14+61.9%11.0% | 8.8—17.0% | |
| Lease liabilities (non-current) | 1.3−0.1%1.0% | 1.3—2.5% | |
| Total liabilities | 31+19.2%24.0% | 26—50.6% | |
| Retained earnings | −101—−77.5% | −71—−137% | |
| Shareholders' equity | 99—76.0% | −71—−136% | |
| Total liabilities and equity | 130+151%100% | 52—100% | |
| Shares outstanding | 27+543%— | 4.1—— | |
| Cash-flow statement | |||
| Depreciation and amortization | 0.3+93.8%0.6% | 0.1—0.5% | |
| Share-based compensation | 1.9+662%3.8% | 0.3—0.9% | |
| Cash from operating activities | −29—−57.4% | −25—−93.7% | |
| Capital expenditure | −0.6—−1.3% | −0.2—−0.7% | |
| Cash from investing activities | −25—−50.5% | −0.2—−0.7% | |
| Cash from financing activities | 100+71.2%198% | 58—215% | |
| Report | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 72—100% | 22+64.9%100% | 19+56.7%100% | 16—100% | 15*—100% | 13—100% | 12—100% | |
| Cost of revenue | 17—23.0% | 4.9+55.4%22.7% | 4.4+36.8%23.2% | 3.7—22.9% | 3.6*—23.5% | 3.1—24.1% | 3.2—26.6% | |
| Gross profit | 55—77.0% | 17+67.9%77.3% | 15+64.0%76.8% | 12—77.1% | 12*—76.5% | 9.9—75.9% | 8.9—73.4% | |
| Research and development | 23—31.9% | 6.4+43.5%29.6% | 6.0+45.2%31.9% | 5.2—32.1% | 5.3*—34.7% | 4.4—34.0% | 4.2—34.4% | |
| Selling and marketing | 46—64.1% | 13+35.3%60.3% | 12+51.5%62.9% | 10—63.9% | 11*—71.3% | 9.6—73.5% | 7.9—65.1% | |
| General and administrative | 29—40.0% | 10.0+103%46.3% | 7.6+128%40.2% | 6.2—38.6% | 4.9*—32.0% | 4.9—37.5% | 3.3—27.7% | |
| Operating expenses | 98—136% | 29+54.9%136% | 26+66.4%135% | 22—135% | 21*—138% | 19—145% | 15—127% | |
| Operating income | −42—−59.0% | −13—−58.9% | −11—−58.3% | −9.3—−57.6% | −9.3*—−61.4% | −9.0—−69.1% | −6.5—−53.8% | |
| Interest and finance income | 3.5—4.9% | 0.8−19.1%3.6% | 0.8+150%4.4% | 0.9—5.5% | 1.0*—6.8% | 1.0—7.3% | 0.3—2.8% | |
| Interest expense and finance costs | 1.3—1.8% | 0.3−16.8%1.5% | 0.3−13.8%1.7% | 0.3—1.9% | 0.3*—2.2% | 0.4—2.9% | 0.4—3.0% | |
| Other non-operating income (expense) | 2.3—3.2% | 0.5−10.4%2.1% | 0.5—2.8% | 0.6—3.6% | 0.7*—4.6% | 0.5—3.9% | −0.3—−2.2% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −40—−55.8% | −12—−56.8% | −11—−55.5% | −8.7—−54.0% | −8.6*—−56.8% | −8.5—−65.2% | −6.8—−56.0% | |
| Earnings per share, basic | — | -0.45—— | -0.39—— | -0.32—— | — | -0.40—— | -1.47—— | |
| Earnings per share, diluted | — | -0.45—— | -0.39—— | -0.32—— | — | -0.40—— | -1.47—— | |
| Shares, weighted average (basic) | 27—— | 27+29.5%— | 27+492%— | 27—— | — | 21—— | 4.6—— | |
| Shares, weighted average (diluted) | 27—— | 27+29.5%— | 27+492%— | 27—— | — | 21—— | 4.6—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 36—31.2% | 36−68.8%31.2% | 46+38.2%39.1% | 73—61.5% | 86—65.9% | 115—85.5% | 33—62.8% | |
| Short-term investments | 24—20.8% | 24—20.8% | 24—20.3% | 24—20.2% | 24—18.4% | — | — | |
| Receivables | 17—14.6% | 17+49.5%14.6% | 14+41.8%11.7% | 12—10.3% | 11—8.7% | 11—8.4% | 9.7—18.2% | |
| Inventory | 3.0—2.6% | 3.0+123%2.6% | 2.3+113%1.9% | 2.1—1.7% | 1.8—1.4% | 1.3—1.0% | 1.1—2.0% | |
| Other current assets | 5.4—4.7% | 5.4+60.2%4.7% | 4.2+129%3.6% | 4.0—3.3% | 3.6—2.7% | 3.4—2.5% | 1.8—3.5% | |
| Current assets | 106—91.6% | 106−19.7%91.6% | 110+137%92.7% | 115—97.2% | 127—97.4% | 131—97.5% | 46—86.7% | |
| Property, plant and equipment | 3.6—3.1% | 3.6+204%3.1% | 2.4+147%2.0% | 1.6—1.3% | 1.5—1.1% | 1.2—0.9% | 1.0—1.8% | |
| Right-of-use (leased) assets | 5.7—5.0% | 5.7+187%5.0% | 6.0+178%5.0% | 1.7—1.4% | 1.8—1.4% | 2.0—1.5% | 2.1—4.0% | |
| Total assets | 115—100% | 115−14.5%100% | 118+122%100% | 119—100% | 130—100% | 135—100% | 53—100% | |
| Accounts payable | 3.3—2.9% | 3.3+23.9%2.9% | 3.7+43.5%3.1% | 3.0—2.5% | 4.5—3.4% | 2.7—2.0% | 2.6—4.8% | |
| Current liabilities | 18—15.8% | 18+66.9%15.8% | 12+30.7%10.5% | 9.7—8.2% | 14—11.0% | 11—8.1% | 9.5—17.8% | |
| Lease liabilities (non-current) | 5.6—4.9% | 5.6+270%4.9% | 5.8+242%4.9% | 1.1—0.9% | 1.3—1.0% | 1.5—1.1% | 1.7—3.2% | |
| Total liabilities | 40—34.4% | 40+40.4%34.4% | 34+23.0%28.7% | 27—22.3% | 31—24.0% | 28—20.9% | 28—51.8% | |
| Retained earnings | −132—−115% | −132—−115% | −120—−102% | −110—−92.2% | −101—−77.5% | −92—−68.4% | −84—−157% | |
| Shareholders' equity | 76—65.6% | 76−29.1%65.6% | 84—71.3% | 92—77.7% | 99—76.0% | 107—79.1% | −83—−156% | |
| Total liabilities and equity | 115—100% | 115−14.5%100% | 118+122%100% | 119—100% | 130—100% | 135—100% | 53—100% | |
| Shares outstanding | 27—— | 27+3.0%— | 27+491%— | 27—— | 27—— | 27—— | 4.6—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.5—0.6% | 0.1*+53.7%0.6% | 0.1*—0.7% | 0.1—0.6% | 0.1*—0.6% | 0.1*—0.6% | — | |
| Share-based compensation | 8.0—11.1% | 3.3+366%15.2% | 2.3+780%12.0% | 1.6—10.1% | 0.8*—5.2% | 0.7—5.4% | 0.3—2.1% | |
| Cash from operating activities | −34—−47.9% | −8.7*—−40.2% | −7.4*—−38.8% | −13—−80.7% | −5.3*—−35.1% | −8.5*—−64.7% | — | |
| Capital expenditure | −0.6—−0.8% | −0.3*—−1.3% | −0.1*—−0.6% | −0.1—−0.5% | −0.1*—−0.5% | −0.2*—−1.2% | — | |
| Cash from investing activities | −46—−63.9% | −1.8*—−8.3% | −20*—−104% | −0.2—−1.3% | −24*—−160% | −0.3*—−2.6% | — | |
| Cash from financing activities | 0.8—1.1% | 0.2*−99.8%0.8% | 0.2*—1.3% | 0.4—2.7% | −0.0*—−0.2% | 91*—694% | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Carlsmed, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Carlsmed, Inc.#
$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.
- Health Issues4 reports
- Medicare/Medicaid4 reports
Lobbying firms hired in 2025
Manatt, Phelps, and Phillips $80 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $140 K | — | 3 |
| 2025 | $80 K | — | 4 |
| 2024 | $220 K | — | 6 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Carlsmed Inc” and “Carlsmed, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Carlsmed, Inc. compares in Healthcare
- Market cap$420 M · higher than 43% of 2,013
- Revenue$51 M · higher than 34% of 1,795
- Net margin-55.8% · higher than 22% of 1,485
- Revenue growth86.0% · higher than 88% of 1,003
- Price / sales5.8× · lower than 35% of 1,071
- Price / book4.2× · lower than 35% of 1,245
- FCF yield-7.1% · higher than 47% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Carlsmed, Inc.🇺🇸 | $420 M | — | -55.8% | +86.0% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Carlsmed, Inc.? Verify and update this profile — free
Show Carlsmed, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.